{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Agbioscience","title":"350. Elevate Ventures’ Matt Tyner on the cost of innovation + the role of the investor in this next era of venture capital","html":"","width":"100%","height":180,"duration":1737,"description":"Pitchbook reports that of venture capital deals in 2024, roughly 30% of them were down rounds or flat, meaning their valuation of the companies either went backwards or were the same round to round. It’s a trend that will continue, so how can entrepreneurs break the cycle? Matt Tyner, managing partner of America’s most active venture capital firm – Elevate Ventures, joins today to make sense of what’s ahead and how innovators can succeed. He gets into:  \n\nThe current state of venture capital – and the criticality of taking a step back to understand where things sit today \nInvestors’ increased focus on profitability and not being able to cut your way to growth \nArtificial intelligence as an enabler – not a vertical  \nDoes the future include a shift to debt versus venture \nThe cost of innovation and the role of an investor in this era of venture capital \nWhat the current conversation with portfolio companies looks like for Elevate Ventures \nWhat Matt sees as emerging trends in agbioscience \nThe most important jobs to be done in the industry ","thumbnail_url":"https://img.transistorcdn.com/fNR6XzpB2Kp8cz0_UeZ53to0jw3tZsavgDDSar67UYQ/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8yZWEy/YjI3YzlhYWEzMzdm/NWU0NDIxYmEyMGI2/MmZjZC5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}